Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.

Bai RY, Esposito D, Tam AJ, McCormick F, Riggins GJ, Wade Clapp D, Staedtke V.

Gene Ther. 2019 Jun;26(6):277-286. doi: 10.1038/s41434-019-0080-9. Epub 2019 May 24.

PMID:
31127187
2.

A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, Sandusky G, Stemmer-Rachamimov A, Stuhlmiller TJ, Angus SP, Johnson GL, Nalepa G, Yates CW, Wade Clapp D, Park SJ.

Hum Mol Genet. 2019 Feb 15;28(4):572-583. doi: 10.1093/hmg/ddy361.

PMID:
30335132
3.

A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.

Gehlhausen JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD, Menon K, Lajiness JD, Mwanthi M, Yang X, Yuan J, Territo P, Hutchins G, Nalepa G, Yang FC, Conway SJ, Heinz MG, Stemmer-Rachamimov A, Yates CW, Wade Clapp D.

Hum Mol Genet. 2015 Jan 1;24(1):1-8. doi: 10.1093/hmg/ddu414. Epub 2014 Aug 11.

Supplemental Content

Loading ...
Support Center